Scinai Immunotherapeutics (Scinai Immunotherapeutics) Debt-to-Equity : -7.36 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Debt-to-Equity?

Scinai Immunotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.38 Mil. Scinai Immunotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $19.43 Mil. Scinai Immunotherapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-2.69 Mil. Scinai Immunotherapeutics's debt to equity for the quarter that ended in Sep. 2023 was -7.36.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Scinai Immunotherapeutics's Debt-to-Equity or its related term are showing as below:

SCNI' s Debt-to-Equity Range Over the Past 10 Years
Min: -35.93 Med: -1.83 Max: 29.52
Current: -7.36

During the past 12 years, the highest Debt-to-Equity Ratio of Scinai Immunotherapeutics was 29.52. The lowest was -35.93. And the median was -1.83.

SCNI's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs SCNI: -7.36

Scinai Immunotherapeutics Debt-to-Equity Historical Data

The historical data trend for Scinai Immunotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Debt-to-Equity Chart

Scinai Immunotherapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-3.02

-2.02

-4.60

29.52

-12.24

Scinai Immunotherapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															6.63	-12.24	-4.84	-3.46	-7.36

Competitive Comparison of Scinai Immunotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, Scinai Immunotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scinai Immunotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Debt-to-Equity falls into.

Scinai Immunotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Scinai Immunotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.382	+	21.16)	/	-1.76
	=	-12.24

Scinai Immunotherapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.382	+	19.425)	/	-2.692
	=	-7.36

Scinai Immunotherapeutics (NAS:SCNI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Scinai Immunotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

2F50:Germany

Address

Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR

Website

https://www.biondvax.com

BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.

Executives

Samuel J Moed	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain	director, other: Chairman	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Chief Financial Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin	director	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv	director	STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster	director	11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia	officer: Chief Scientist	6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman	director	21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman	director, officer: Chief Executive Officer	269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark	officer: Chief Operating Officer	27 HAILANOT, HERZLIYA L3 4631214
George Lowell	director	33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green	director	354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6